Bridge BioResearch

Bridge Bioresearch PLC is a drug development company focused on general Phase 2a clinical trials, as well as novel drugs for treating a wide range of metabolic disorders in the field of lifestyle-induced diseases, such as obesity, type 2 diabetes, and hypertension. Its expertise includes scientific due diligence and animal model selection to further validate proof-of-concept testing, as well as the design and project management of preclinical and clinical trials. Formerly known as Bridge Bioresearch International Limited, it was renamed Bridge Bioresearch PLC in March 2007.